Revolution Medicines(NASDAQ) RVMDW

Market CapN/A

Since IPO (2023)+1,046%

5 YearN/A

1 Year+6,841%

1 Month+20%

$11.81

+3.05%

+0.35Today

Revolution Medicines last closing stock price
Metric	Price	Date
Last close	USD 11.46	2026-08-31

Revolution Medicines stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-4.74%	USD 12.03	2026-08-24
1 month	+19.81%	USD 9.57	2026-07-31
3 month	+94.9%	USD 5.88	2026-06-02
Year to date	+1,119.28%	USD 0.94	2025-12-31
1 year	+6,841.25%	USD 0.17	2025-08-29
Since inception	+1,046.11%	USD 1.00	2023-11-17

Revolution Medicines Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.77B

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Price

$11.81

Volume

20,815

Open

$11.63

Price

$11.81

Volume

20,815

Open

$11.63

Previous Close

$11.81

Daily Range

$11.29 - $11.81

52-Week Range

$0.16 - $13.44

Estimated Earnings Date

Nov 11, 2026

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Price

$11.81

Volume

20,815

Open

$11.63

Previous Close

$11.81

Daily Range

$11.29 - $11.81

52-Week Range

$0.16 - $13.44

Estimated Earnings Date

Nov 11, 2026

RVMDW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Revolution Medicines

Revolution Medicines, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancers driven by RAS pathway dysregulation. The company is advancing a portfolio of RAS(ON) inhibitors and companion inhibitors aimed at providing targeted treatment options for patients.

Products and Services

RAS(ON) inhibitors for various RAS mutations
Dedicated RAS companion inhibitors for synergistic treatment
Innovative therapies in clinical development for cancer treatment

Growth Outlook

Strong pipeline with multiple candidates in Phase 1 and Phase 2 trials
Significant investment in research and development, exceeding $394 million in Q2 2026
Potential for market expansion as RAS-targeted therapies gain traction

Financial Highlights

Cash and short-term investments totaled approximately $3.94 billion as of Q2 2026
Operating expenses reached $505 million in Q2 2026, reflecting ongoing development efforts
Net income for Q2 2026 was reported at -$644 million, indicating continued investment in growth

Revolution Medicines, Inc. operates in a dynamic sector with a focus on addressing significant unmet medical needs in oncology. The company's innovative approach to targeting RAS pathway dysregulation positions it well for future growth. With a robust pipeline and substantial financial resources, Revolution Medicines is poised to make a meaningful impact in the biopharmaceutical landscape. The ongoing clinical trials and strategic investments in research and development highlight the company's commitment to advancing cancer therapies.

AI Generated • Aug 27, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Redwood City, CA 94063, US

RVMDW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-96.44%

Return on Capital

-66.05%

Return on Assets

-40.90%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

20.82K

Avg. Volume

60.62K

Financials (TTM)

Gross Profit

-$9.24M

Operating Income

-$1.63B

EBITDA

-$1.70B

Operating Cash Flow

-$1.58B

Capital Expenditure

-$10.64M

Free Cash Flow

-$1.59B

Cash & ST Invst.

$3.94B

Total Debt

$641.93M

Revolution Medicines Performance Analysis

Revolution Medicines sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Revolution Medicines sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-22.9%
Q4	2025-12-31	-18.0%
Q1	2026-03-31	-20.5%
Q2	2026-06-30	-33.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

883

N/A

Net Income

-$644.37M

-160.1%

EBITDA

-$620.59M

-154.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$3.94B

+84.3%

Total Debt

$641.93M

+383.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$625.18M

+422.3%

Short Term Debt

$16.75M

+28.0%

Return on Assets

-40.90%

N/A

Return on Invested Capital

-41.00%

N/A

Free Cash Flow

-$745.31M

-225.2%

Operating Cash Flow

-$741.48M

-234.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ESLAEstrella Immunopharma, Inc.

ESLAEstrella Immunopharma, Inc.$0.69-4.62%

VTVTvTv Therapeutics Inc.

VTVTvTv Therapeutics Inc.$31.95-0.16%

TELOTelomir Pharmaceuticals, Inc. Common Stock

TELOTelomir Pharmaceuticals, Inc. Common Stock$1.10-1.79%

FBIOFortress Biotech, Inc.

FBIOFortress Biotech, Inc.$2.68-2.01%

COEPCoeptis Therapeutics Holdings, Inc.

COEPCoeptis Therapeutics Holdings, Inc.$10.99-8.57%

ACRVAcrivon Therapeutics, Inc. Common Stock

ACRVAcrivon Therapeutics, Inc. Common Stock$2.07-0.96%

ICCCImmuCell Corporation

ICCCImmuCell Corporation$9.92+1.33%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$14.06+0.06%

NVDANvidia

NVDANvidia$217.44-0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.33-0.06%

INTCIntel

INTCIntel$88.97-0.01%

ONDSOndas

ONDSOndas$7.04-0.08%

NUNu Holdings

NUNu Holdings$14.46-0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.38-0.02%

Questions About RVMDW

What is the current price of Revolution Medicines?

Revolution Medicines is trading at $11.81 per share.

What is the 52-week range for Revolution Medicines?

Over the past 52 weeks, Revolution Medicines has traded between $0.16 and $13.44.

How much debt does Revolution Medicines have?

Revolution Medicines total debt is unavailable.

How much cash does Revolution Medicines have on hand?

Revolution Medicines does not have cash on hand data available.

What is Revolution Medicines’s dividend yield?

Revolution Medicines does not currently have a dividend yield.

Revolution Medicines(NASDAQ) RVMDW

Revolution Medicines Financials at a Glance

RVMDW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Revolution Medicines

RVMDW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Revolution Medicines Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RVMDW

What is the current price of Revolution Medicines?

What is the 52-week range for Revolution Medicines?

How much debt does Revolution Medicines have?

How much cash does Revolution Medicines have on hand?

What is Revolution Medicines’s dividend yield?

Premium Investing Services